About hbm holdings - HBMHF
HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. It operates through the following geographical segments: Europe, Mainland China, United States, and Others. The company was founded by Xiao Xiang Chen, Qi He, Schweizer Liang, Mai Jing Liao, Xiao Xi Liu, and Jing Song Wang on July 20, 2016 and is headquartered in Suzhou, China.
HBMHF At a Glance
HBM Holdings Ltd.
Suzhou Industrial Park, Building A3
Suzhou, Shanghai 215123
| Phone | 86-21-65790025 | Revenue | 38.10M | |
| Industry | Pharmaceuticals: Other | Net Income | 2.78M | |
| Sector | Health Technology | Employees | 183 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
HBMHF Valuation
| P/E Current | 305.556 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 66.513 |
| Price to Sales Ratio | 4.855 |
| Price to Book Ratio | 1.471 |
| Price to Cash Flow Ratio | 5.44 |
| Enterprise Value to EBITDA | -96.547 |
| Enterprise Value to Sales | 2.053 |
| Total Debt to Enterprise Value | 0.784 |
HBMHF Efficiency
| Revenue/Employee | 208,196.721 |
| Income Per Employee | 15,180.328 |
| Receivables Turnover | 1.682 |
| Total Asset Turnover | 0.172 |
HBMHF Liquidity
| Current Ratio | 2.824 |
| Quick Ratio | 2.79 |
| Cash Ratio | 2.415 |
HBMHF Profitability
| Gross Margin | 80.706 |
| Operating Margin | -9.698 |
| Pretax Margin | 9.814 |
| Net Margin | 7.291 |
| Return on Assets | 1.253 |
| Return on Equity | 2.273 |
| Return on Total Capital | 1.495 |
| Return on Invested Capital | 2.00 |
HBMHF Capital Structure
| Total Debt to Total Equity | 49.289 |
| Total Debt to Total Capital | 33.016 |
| Total Debt to Total Assets | 28.528 |
| Long-Term Debt to Equity | 3.80 |
| Long-Term Debt to Total Capital | 2.545 |